Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin

mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia

(2018) Irene Sebastianutto et al.   CURRENT OPINION IN PHARMACOLOGY

Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3−/−Mice, a Genetic Model of Parkinson's Disease

(2018) Luz M. Suarez et al.   JOURNAL OF NEUROSCIENCE

L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia

(2016) Luz M Suarez et al.   CEREBRAL CORTEX

Fragment C Domain of Tetanus Toxin Mitigates Methamphetamine Neurotoxicity and Its Motor Consequences in Mice

(2016) Liliana Mendieta et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1

(2016) Jonathan M. Payne et al.   NEUROLOGY

A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I

(2016) Carrie E. Bearden et al.   Annals of Clinical and Translational Neurology

Activation of DREAM (Downstream Regulatory Element Antagonistic Modulator), a Calcium-Binding Protein, Reduces L-DOPA-Induced Dyskinesias in Mice

(2015) Irene Ruiz-DeDiego et al.   BIOLOGICAL PSYCHIATRY

Dopaminergic regulation of olfactory type G-protein α subunit expression in the striatum

(2015) I. Ruiz-DeDiego et al.   MOVEMENT DISORDERS

Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3−/− aphakia mice

(2015) Oscar Solís et al.   NEUROBIOLOGY OF DISEASE

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

(2015) Matthieu F. Bastide et al.   PROGRESS IN NEUROBIOLOGY

Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation

(2014) Corina Anastasaki et al.   HUMAN MOLECULAR GENETICS

Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions

(2014) Rolf Heumann et al.   JOURNAL OF NEUROCHEMISTRY

Mechanisms of Dopamine D1 Receptor-Mediated ERK1/2 Activation in the Parkinsonian Striatum and Their Modulation by Metabotropic Glutamate Receptor Type 5

(2014) T. Fieblinger et al.   JOURNAL OF NEUROSCIENCE

L-DOPA Treatment Selectively Restores Spine Density in Dopamine Receptor D2–Expressing Projection Neurons in Dyskinetic Mice

(2013) Luz M. Suárez et al.   BIOLOGICAL PSYCHIATRY

Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1

(2013) Florian Mainberger et al.   BMC Neurology

Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease

(2013) Ramiro González-Aparicio et al.   NEUROBIOLOGY OF DISEASE

Methamphetamine Causes Degeneration of Dopamine Cell Bodies and Terminals of the Nigrostriatal Pathway Evidenced by Silver Staining

(2013) Sara Ares-Santos et al.   NEUROPSYCHOPHARMACOLOGY

L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: Insights into regulation and function

(2012) Isabel Espadas et al.   NEUROBIOLOGY OF DISEASE

Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients

(2012) François Tison et al.   PARKINSONISM & RELATED DISORDERS

PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice

(2011) Jacquelyn A. Brown et al.   EXPERIMENTAL NEUROLOGY

Dopamine D1 receptor deletion strongly reduces neurotoxic effects of methamphetamine

(2011) S. Ares-Santos et al.   NEUROBIOLOGY OF DISEASE

Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation

(2011) Mario Gustavo Murer et al.   Frontiers in Neuroanatomy

L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission

(2011) Michael Feyder et al.   Frontiers in Behavioral Neuroscience

Ras?ERK Signaling in Behavior: Old Questions and New Perspectives

(2011) Stefania Fasano et al.   Frontiers in Behavioral Neuroscience

Molecular and Cellular Mechanisms of Learning Disabilities: A Focus on NF1

(2010) C. Shilyansky et al.   Annual Review of Neuroscience

Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia

(2010) Emanuela Santini et al.   PLoS One

Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors

(2010) H. S. Bateup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia

(2010) S. Fasano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation

(2009) Sanja Darmopil et al.   BIOLOGICAL PSYCHIATRY

Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) Controls Activation of Extracellular Signal-Regulated Kinase (ERK) Signaling in the Striatum and Long-Term Behavioral Responses to Cocaine

(2009) Stefania Fasano et al.   BIOLOGICAL PSYCHIATRY

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Selective Vulnerability in Striosomes and in the Nigrostriatal Dopaminergic Pathway After Methamphetamine Administration

(2009) Noelia Granado et al.   NEUROTOXICITY RESEARCH

Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning

(2008) Yijun Cui et al.   CELL

l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice

(2008) Emanuela Santini et al.   JOURNAL OF NEUROCHEMISTRY

The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of L-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease

(2008) S. Schuster et al.   JOURNAL OF NEUROSCIENCE